Analyst Ratings for Denali Therapeutics Inc. (DNLI)
DNLI Rating Summary
DNLI Price Target Summary
- Highest: $42.00 (H.C. Wainwright)
- Lowest: $25.00 (UBS)
- Average: $35.08
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$35.08 (+50.5%)
* Over Last 12-Mos
Rating Score: 8.8 / 10
Percentile Rank: 88%
Avg. $ Target:
$35.08 (+50.5%)
* Over Last 12-Mos
Rating Score: 8.8 / 10
Percentile Rank: 88%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/24/2026 | Wolfe Research | Rudy Li | New Coverage | Peerperform (N/A) |
N/A (N/A) |
20.19 (23.31) |
15.45% | Details |
| 1/7/2026 | UBS » Updated 6/16/2026 |
Michael Yee | New Coverage | Buy (N/A) |
25.00 (25.00) |
16.02 (23.31) |
45.51% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
